Copyright Reports & Markets. All rights reserved.

Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Professional Survey Report 2019

Request for Sample of this report
Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Glucagon Like Peptide-1 (GLP-1) Agonists

      • 1.1 Definition of Glucagon Like Peptide-1 (GLP-1) Agonists
      • 1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Type
        • 1.2.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 Exenatied
        • 1.2.3 Liraglutide
        • 1.2.4 Lixisenatide
        • 1.2.5 Abliglutide
        • 1.2.6 Dulaglutide
      • 1.3 Glucagon Like Peptide-1 (GLP-1) Agonists Segment by Applications
        • 1.3.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Hospital
        • 1.3.3 Pharmacy
      • 1.4 Global Glucagon Like Peptide-1 (GLP-1) Agonists Overall Market
        • 1.4.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue (2014-2025)
        • 1.4.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production (2014-2025)
        • 1.4.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)
        • 1.4.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)
        • 1.4.5 China Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)
        • 1.4.6 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)
        • 1.4.8 India Glucagon Like Peptide-1 (GLP-1) Agonists Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
      • 2.3 Manufacturing Process Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists
      • 2.4 Industry Chain Structure of Glucagon Like Peptide-1 (GLP-1) Agonists

      3 Development and Manufacturing Plants Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Glucagon Like Peptide-1 (GLP-1) Agonists
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Glucagon Like Peptide-1 (GLP-1) Agonists Production and Capacity Analysis
      • 4.2 Glucagon Like Peptide-1 (GLP-1) Agonists Revenue Analysis
      • 4.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price Analysis
      • 4.4 Market Concentration Degree

      5 Glucagon Like Peptide-1 (GLP-1) Agonists Regional Market Analysis

      • 5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Production by Regions
        • 5.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production by Regions
        • 5.1.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Regions
      • 5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Regions
      • 5.3 North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.3.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.3.2 North America Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export
      • 5.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.4.1 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.4.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export
      • 5.5 China Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.5.1 China Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.5.2 China Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export
      • 5.6 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.6.1 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.6.2 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export
      • 5.7 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.7.1 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.7.2 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export
      • 5.8 India Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis
        • 5.8.1 India Glucagon Like Peptide-1 (GLP-1) Agonists Production
        • 5.8.2 India Glucagon Like Peptide-1 (GLP-1) Agonists Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Glucagon Like Peptide-1 (GLP-1) Agonists Import and Export

      6 Glucagon Like Peptide-1 (GLP-1) Agonists Segment Market Analysis (by Type)

      • 6.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Production by Type
      • 6.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Revenue by Type
      • 6.3 Glucagon Like Peptide-1 (GLP-1) Agonists Price by Type

      7 Glucagon Like Peptide-1 (GLP-1) Agonists Segment Market Analysis (by Application)

      • 7.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption by Application
      • 7.2 Global Glucagon Like Peptide-1 (GLP-1) Agonists Consumption Market Share by Application (2014-2019)

      8 Glucagon Like Peptide-1 (GLP-1) Agonists Major Manufacturers Analysis

      • 8.1 Novo Nordisk
        • 8.1.1 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.1.2 Novo Nordisk Product Introduction, Application and Specification
        • 8.1.3 Novo Nordisk Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 AstraZeneca
        • 8.2.1 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.2.2 AstraZeneca Product Introduction, Application and Specification
        • 8.2.3 AstraZeneca Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Eli Lily
        • 8.3.1 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.3.2 Eli Lily Product Introduction, Application and Specification
        • 8.3.3 Eli Lily Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 GSK
        • 8.4.1 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.4.2 GSK Product Introduction, Application and Specification
        • 8.4.3 GSK Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Sanofi
        • 8.5.1 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.5.2 Sanofi Product Introduction, Application and Specification
        • 8.5.3 Sanofi Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 Bristol-Myers Squibb
        • 8.6.1 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.6.2 Bristol-Myers Squibb Product Introduction, Application and Specification
        • 8.6.3 Bristol-Myers Squibb Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Amylin
        • 8.7.1 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Production Sites and Area Served
        • 8.7.2 Amylin Product Introduction, Application and Specification
        • 8.7.3 Amylin Glucagon Like Peptide-1 (GLP-1) Agonists Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served

      9 Development Trend of Analysis of Glucagon Like Peptide-1 (GLP-1) Agonists Market

      • 9.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Trend Analysis
        • 9.1.1 Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Glucagon Like Peptide-1 (GLP-1) Agonists Regional Market Trend
        • 9.2.1 North America Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
        • 9.2.2 Europe Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
        • 9.2.3 China Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
        • 9.2.4 Japan Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
        • 9.2.5 Southeast Asia Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
        • 9.2.6 India Glucagon Like Peptide-1 (GLP-1) Agonists Forecast 2019-2025
      • 9.3 Glucagon Like Peptide-1 (GLP-1) Agonists Market Trend (Product Type)
      • 9.4 Glucagon Like Peptide-1 (GLP-1) Agonists Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Glucagon Like Peptide-1 (GLP-1) Agonists Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Glucagon Like Peptide-1 (GLP-1) Agonists market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Glucagon Like Peptide-1 (GLP-1) Agonists volume and value at global level, regional level and company level. From a global perspective, this report represents overall Glucagon Like Peptide-1 (GLP-1) Agonists market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Glucagon Like Peptide-1 (GLP-1) Agonists in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Glucagon Like Peptide-1 (GLP-1) Agonists manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Novo Nordisk
        AstraZeneca
        Eli Lily
        GSK
        Sanofi
        Bristol-Myers Squibb
        Amylin
        ...

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        Exenatied
        Liraglutide
        Lixisenatide
        Abliglutide
        Dulaglutide

        Segment by Application
        Hospital
        Pharmacy

        Buy now